Details
Stereochemistry | MIXED |
Molecular Formula | C24H33NO3.C6H8O7 |
Molecular Weight | 575.6472 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 0 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)CC(O)(CC(O)=O)C(O)=O.CCN(CC)CCOC(=O)C(CC1CCCO1)CC2=C3C=CC=CC3=CC=C2
InChI
InChIKey=LKLQMEYKQKAQCX-UHFFFAOYSA-N
InChI=1S/C24H33NO3.C6H8O7/c1-3-25(4-2)14-16-28-24(26)21(18-22-12-8-15-27-22)17-20-11-7-10-19-9-5-6-13-23(19)20;7-3(8)1-6(13,5(11)12)2-4(9)10/h5-7,9-11,13,21-22H,3-4,8,12,14-18H2,1-2H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)
Molecular Formula | C6H8O7 |
Molecular Weight | 192.1235 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C24H33NO3 |
Molecular Weight | 383.5237 |
Charge | 0 |
Count |
|
Stereochemistry | MIXED |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/1369714
Curator's Comment: description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/1369714
Naftidrofuryl (INN), also known as nafronyl or as the oxalate salt naftidrofuryl oxalate or nafronyl oxalate, is a vasodilator used in the management of peripheral and cerebral vascular disorders. The drug act as a selective antagonist of 5-HT2 receptors. Naftidrofuryl is marketed under a variety of trade names, including Artocoron, Azunaftil, Di-Actane, Dusodril, Enelbin, Frilix, Gevatran, Iridus, Iridux, Luctor, Nafti, Naftoling, Naftodril, Nafoxal, Praxilene, Sodipryl retard, and Vascuprax. Praxilene belongs to a group of medicines known as ‘metabolic activators’. These are used to treat different types of blood circulation problems. Praxilene allows the body to make better use of the oxygen in your blood. Praxilene is used to treat the following symptoms: cramp-like pains; cramps in legs at night; severe pain in r legs when people are resting (rest pain); pale or blue fingers or toes which get worse when it is cold; numbness, tingling or burning feelings in the fingers or toes (Raynaud’s syndrome or acrocyanosis); open sores on the legs or feet (trophic ulcers); poor circulation caused by diabetes (diabetic arteriopathy).
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2095200 Sources: http://www.ncbi.nlm.nih.gov/pubmed/1369714 |
0.06 µM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Praxilene Approved UseUnknown Launch Date2016 |
PubMed
Title | Date | PubMed |
---|---|---|
New treatment options in intermittent claudication: the US experience. | 2001 Apr |
|
Naftidrofuryl in quality of life (NIQOL). A Belgian study. | 2001 Dec |
|
Treatment alternatives for nocturnal leg cramps. | 2001 May 21 |
|
[Current EMNID survey on peripheral arterial occlusive disease]. | 2002 |
|
Effect of naftidrofuryl on intramuscular partial oxygen pressure (pO2) prior to, during and after physical load on the treadmill in apparently healthy subjects. | 2002 |
|
Findings of the Naftidrofuryl in Quality of Life (NIQOL) European study program. | 2002 Mar |
|
[Evidence-based therapy of intermittent claudication]. | 2004 |
|
[Secondary prevention and conservative therapy of obliterative arteriosclerosis]. | 2004 May 16 |
|
Naftidrofuryl: a review of its use in the treatment of intermittent claudication. | 2005 |
|
Pharmacokinetics of naftidrofuryl in patients with renal impairment. | 2005 |
|
Cost effectiveness of cilostazol compared with naftidrofuryl and pentoxifylline in the treatment of intermittent claudication in the UK. | 2005 Jun |
|
[Vasoactive agents and prostanoids in the therapy of PAD: facts, questions, disproven assumptions]. | 2006 Aug |
|
Management of peripheral arterial disease in the elderly: focus on cilostazol. | 2008 |
|
Current management of intermittent claudication: the role of pharmacological and nonpharmacological symptom-directed therapies. | 2009 Jul |
|
Silence of the limbs pharmacological symptomatic treatment of intermittent claudication. | 2010 May |
|
Screening of a chemical library reveals novel PXR-activating pharmacologic compounds. | 2015 Jan 5 |
Patents
Sample Use Guides
The recommended dose is one or two capsules (100 mg naftidrofuryl oxalate) three times a day, for a minimum of three months
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/7863151
After culture in a rat serum enriched with naftidrofuryl at concentration of 20 uM, we observed a protective effect of this drug toward the disruption of axonal microtubules by vinka alkaloids
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 09:40:58 GMT 2023
by
admin
on
Sat Dec 16 09:40:58 GMT 2023
|
Record UNII |
1BB8I7MT98
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
286-639-8
Created by
admin on Sat Dec 16 09:40:58 GMT 2023 , Edited by admin on Sat Dec 16 09:40:58 GMT 2023
|
PRIMARY | |||
|
184479
Created by
admin on Sat Dec 16 09:40:58 GMT 2023 , Edited by admin on Sat Dec 16 09:40:58 GMT 2023
|
PRIMARY | |||
|
85293-34-1
Created by
admin on Sat Dec 16 09:40:58 GMT 2023 , Edited by admin on Sat Dec 16 09:40:58 GMT 2023
|
PRIMARY | |||
|
1BB8I7MT98
Created by
admin on Sat Dec 16 09:40:58 GMT 2023 , Edited by admin on Sat Dec 16 09:40:58 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
|